Article summary
This observational preprint (n=30) followed people with treatment-resistant depression through eight intranasal esketamine treatments. Higher baseline metabolic burden was associated with greater improvement in depression, and fasting glucose decreased, whereas inflammatory and neurotrophic measures showed no consistent treatment-related changes.
Continue to the original publication for the complete article.